The US Food and Drug Administration has approved eltrombopag under the trade name Promacta as a treatment of chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or surgical removal of the spleen, in November 2008.
Eltrombopag has got authorization for use in EU, along with Ireland, India, Bahrain, Chile, Russia, Japan, Turkey, Taiwan, Kuwait, Singapore and Australia, under the trade name Revolade.